NCT06902103View on ClinicalTrials.gov

Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 26, 2023

Study Completion Date

January 18, 2024

Conditions

Pain

Interventions

DRUG

Nabufine Hydrochloride Injection

PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose

DRUG

Nabufine Hydrochloride Injection

PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose

Trial Locations (1)

Unknown

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

INDUSTRY

NCT06902103 - Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter